– Reuters
SVB Leerink Maintains Market Perform on bluebird bio, Raises Price Target to $9
SVB Leerink analyst Mani Foroohar maintains bluebird bio (NASDAQ:BLUE) with a Market Perform and raises the price target from $8 to $9.
Related Posts
Atlantic Equities Upgrades Warner Music Gr to Overweight, Raises Price Target to $41
Atlantic Equities analyst Hamilton Faber upgrades Warner Music Gr (NASDAQ:WMG) from Neutral to Overweight and raises the price target from $34 to $41.
Broadway Financial Q3 EPS $0.02
Broadway Financial (NASDAQ:BYFC) reported quarterly earnings of $0.02 per share.
McConnell, Summers, Cramer, Hartnett, And Powell Shape The Narrative: Week’s Most-Read Stories On Economy
The past week in the economic segment was marked by significant developments and predictions. From Mitch McConnell’s criticism…